Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | CD74 | P04233 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659688 | 1.00 | PPARG (0.40) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL13114555 | 0.88 | AR (0.38) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL14459759 | 0.86 | PPARG (0.46) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL5175340 | 0.86 | PPARG (0.46) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL13282969 | 0.86 | FGFR1 (0.41) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL5175221 | 0.85 | PPARG (0.47) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL5630819 | 0.85 | PPARG (0.47) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL5822442 | 0.85 | PPARG (0.47) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL3548517 | 0.84 | PPARG (0.40) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL5176154 | 0.83 | NR1H2 (0.41) | PPARGPPARDPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-1907381-A4 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1907381-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| EP-1709014-B1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007008501-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1709014-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070905-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.